A phase I study of AVE1642, a human monoclonal antibody–blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback